Caleb Jones, a player for the Pittsburgh Penguins, faces a 20-game suspension due to a violation of the NHL/NHLPA Performance Enhancing Substances Program. The league announced this disciplinary action on Wednesday.
Details of the Suspension
Jones, 28, claims that the positive test resulted from receiving exosome therapy for a documented injury from an external provider. He stated, “I believe that my positive test was related to a contaminated substance associated with that treatment.” He expressed regret for the impact of his actions, saying he has let down his teammates, the Penguins organization, and their fans.
Contract and Career Overview
This season, Jones signed a two-year contract worth $1.8 million with the Penguins. However, injuries have limited his performance, resulting in just one assist over seven games. In his career, he has played 255 games, accumulating 14 goals and 42 assists. He has previously played for the Edmonton Oilers, Chicago Blackhawks, Los Angeles Kings, and the Penguins.
Organizational Response
- Kyle Dubas, Penguins general manager, commented on the situation.
- Dubas noted that Jones was forthcoming throughout the process.
- He acknowledged that Jones accepted full responsibility for his actions.
Despite not intentionally using a prohibited substance, Jones understands that players are accountable for everything they consume. The suspension underscores the strict regulations within the NHL regarding performance-enhancing substances.
